Johns Hopkins University

In December 2014, Compugen announced a multi-year immuno-oncology research collaboration with The Johns Hopkins University, under the direction of Drew Pardoll, M.D., Ph.D. and Charles Drake, M.D., Ph.D., both members of Compugen’s Scientific Advisory Board and faculty at Johns Hopkins University School of Medicine. The collaboration focuses on further evaluation of selected novel B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer. This evaluation includes the candidates’ differentiation profile with respect to known checkpoints and their potential to serve either for monotherapy or in combination with other cancer treatments.